Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression
Abstract Exosomes are involved in a wide range of biological processes in human cells. Considerable evidence suggests that engineered exosomes (eExosomes) containing therapeutic agents can attenuate the oncogenic activity of human cancer cells. Despite its biomedical relevance, no information has be...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9ed74c814c914ce78df8087aa1a83150 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9ed74c814c914ce78df8087aa1a83150 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9ed74c814c914ce78df8087aa1a831502021-12-02T17:05:11ZEngineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression10.1038/s41598-021-85242-12045-2322https://doaj.org/article/9ed74c814c914ce78df8087aa1a831502021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85242-1https://doaj.org/toc/2045-2322Abstract Exosomes are involved in a wide range of biological processes in human cells. Considerable evidence suggests that engineered exosomes (eExosomes) containing therapeutic agents can attenuate the oncogenic activity of human cancer cells. Despite its biomedical relevance, no information has been available for oral squamous cell carcinoma (OSCC), and therefore the development of specific OSCC-targeting eExosomes (octExosomes) is urgently needed. We demonstrated that exosomes from normal fibroblasts transfected with Epstein–Barr Virus Induced-3 (EBI3) cDNA were electroporated with siRNA of lymphocyte cytoplasmic protein 1 (LCP1), as octExosomes, and a series of experiments were performed to evaluate the loading specificity/effectiveness and their anti-oral cancer cell activities after administration of octExosomes. These experiments revealed that octExosomes were stable, effective for transferring siLCP1 into OSCC cells and LCP1 was downregulated in OSCC cells with octExosomes as compared with their counterparts, leading to a significant tumor-suppressive effect in vitro and in vivo. Here we report the development of a new valuable tool for inhibiting tumor cells. By engineering exosomes, siLCP1 was transferred to specifically suppress oncogenic activity of OSCC cells. Inhibition of other types of human malignant cells merits further study.Yutaro KaseKatsuhiro UzawaSho WagaiShusaku YoshimuraJun-Ichiro YamamotoYuriko ToedaMegumi OkuboKeitaro EizukaToshiaki AndoTakafumi NobuchiKohei KawasakiTomoaki SaitoManabu IyodaDai NakashimaAtsushi KasamatsuHideki TanzawaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yutaro Kase Katsuhiro Uzawa Sho Wagai Shusaku Yoshimura Jun-Ichiro Yamamoto Yuriko Toeda Megumi Okubo Keitaro Eizuka Toshiaki Ando Takafumi Nobuchi Kohei Kawasaki Tomoaki Saito Manabu Iyoda Dai Nakashima Atsushi Kasamatsu Hideki Tanzawa Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression |
| description |
Abstract Exosomes are involved in a wide range of biological processes in human cells. Considerable evidence suggests that engineered exosomes (eExosomes) containing therapeutic agents can attenuate the oncogenic activity of human cancer cells. Despite its biomedical relevance, no information has been available for oral squamous cell carcinoma (OSCC), and therefore the development of specific OSCC-targeting eExosomes (octExosomes) is urgently needed. We demonstrated that exosomes from normal fibroblasts transfected with Epstein–Barr Virus Induced-3 (EBI3) cDNA were electroporated with siRNA of lymphocyte cytoplasmic protein 1 (LCP1), as octExosomes, and a series of experiments were performed to evaluate the loading specificity/effectiveness and their anti-oral cancer cell activities after administration of octExosomes. These experiments revealed that octExosomes were stable, effective for transferring siLCP1 into OSCC cells and LCP1 was downregulated in OSCC cells with octExosomes as compared with their counterparts, leading to a significant tumor-suppressive effect in vitro and in vivo. Here we report the development of a new valuable tool for inhibiting tumor cells. By engineering exosomes, siLCP1 was transferred to specifically suppress oncogenic activity of OSCC cells. Inhibition of other types of human malignant cells merits further study. |
| format |
article |
| author |
Yutaro Kase Katsuhiro Uzawa Sho Wagai Shusaku Yoshimura Jun-Ichiro Yamamoto Yuriko Toeda Megumi Okubo Keitaro Eizuka Toshiaki Ando Takafumi Nobuchi Kohei Kawasaki Tomoaki Saito Manabu Iyoda Dai Nakashima Atsushi Kasamatsu Hideki Tanzawa |
| author_facet |
Yutaro Kase Katsuhiro Uzawa Sho Wagai Shusaku Yoshimura Jun-Ichiro Yamamoto Yuriko Toeda Megumi Okubo Keitaro Eizuka Toshiaki Ando Takafumi Nobuchi Kohei Kawasaki Tomoaki Saito Manabu Iyoda Dai Nakashima Atsushi Kasamatsu Hideki Tanzawa |
| author_sort |
Yutaro Kase |
| title |
Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression |
| title_short |
Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression |
| title_full |
Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression |
| title_fullStr |
Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression |
| title_full_unstemmed |
Engineered exosomes delivering specific tumor-suppressive RNAi attenuate oral cancer progression |
| title_sort |
engineered exosomes delivering specific tumor-suppressive rnai attenuate oral cancer progression |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/9ed74c814c914ce78df8087aa1a83150 |
| work_keys_str_mv |
AT yutarokase engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT katsuhirouzawa engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT showagai engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT shusakuyoshimura engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT junichiroyamamoto engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT yurikotoeda engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT megumiokubo engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT keitaroeizuka engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT toshiakiando engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT takafuminobuchi engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT koheikawasaki engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT tomoakisaito engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT manabuiyoda engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT dainakashima engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT atsushikasamatsu engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression AT hidekitanzawa engineeredexosomesdeliveringspecifictumorsuppressivernaiattenuateoralcancerprogression |
| _version_ |
1718381805454753792 |